文献速递妇科肿瘤

奥维穆洛基因纳尼瓦西瑞普维预免疫化疗在重度经治铂耐药或铂难治性卵巢癌患者中的临床活性:非随机2期VIRO-15临床试验

Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项开放标签、非随机、多中心2期VIRO-15试验纳入27例重度经治的铂耐药或铂难治性卵巢癌患者,评估腹腔注射奥维穆洛基因纳尼瓦西瑞普维(Olvi-Vec)病毒治疗后联合铂类双药化疗(联合或不联合贝伐珠单抗)的抗肿瘤活性与安全性。结果显示RECIST 1.1标准ORR为54%、中位PFS 11.0个月、中位OS 15.7个月,安全性可控,作者认为这些假设生成性结果值得在确证性3期试验中进一步评估。

要点

  • RECIST 1.1标准ORR为54%(95%CI 33%-74%),DCR为88%(21/24)。
  • 中位PFS为11.0个月(95%CI 6.7-13.0个月),6个月PFS率为77%。
  • 最常见TRAE为发热(任何级别63.0%、3级3.7%)和腹痛(任何级别51.9%、3级7.4%),无4级TRAE。

核心结论

  • 在2期非随机临床试验中,Olvi-Vec后接铂类化疗联合或不联合贝伐珠单抗的免疫化疗在PRROC患者中显示出有前景的ORR和PFS,安全性可控。
  • 作者认为这些假设生成性结果值得在确证性3期试验中进一步评估。

研究设计与样本

  • 开放标签、非随机、多中心2期VIRO-15临床试验,纳入2016年9月至2019年9月期间末线治疗后进展的PRROC患者。
  • 共纳入27例重度经治患者,铂耐药14例、铂难治13例;中位(范围)年龄62(35-78)岁,中位(范围)既往治疗线数4(2-9)线。
  • 数据截止日期为2022年3月31日,数据分析时间为2022年4月至2022年9月。
  • 干预为经临时腹腔透析导管给予Olvi-Vec连续2天每日剂量(3×10^9 pfu/d),随后给予铂类双药化疗联合或不联合贝伐珠单抗。
  • 主要终点为RECIST 1.1和CA-125评估的ORR及PFS;次要终点包括DOR、DCR、安全性和OS。

主要发现

  • 所有患者均完成两次Olvi-Vec输注和化疗;中位随访时间47.0个月(95%CI 35.9个月至NA)。
  • 总体RECIST 1.1标准ORR为54%(95%CI 33%-74%),DOR为7.6个月(95%CI 3.7-9.6个月),DCR为88%(21/24)。
  • CA-125标准ORR为85%(95%CI 65%-96%)。
  • RECIST 1.1标准中位PFS为11.0个月(95%CI 6.7-13.0个月),6个月PFS率为77%;铂耐药组中位PFS为10.0个月(95%CI 6.4个月至NA),铂难治组为11.4个月(95%CI 4.3-13.2个月)。
  • 全部患者中位OS为15.7个月(95%CI 12.3-23.8个月),铂耐药组为18.5个月(95%CI 11.3-23.8个月),铂难治组为14.7个月(95%CI 10.8-33.6个月)。

关键数值与推荐

  • RECIST 1.1标准ORR为54%(95%CI 33%-74%),DCR为88%(21/24)。
  • CA-125标准ORR为85%(95%CI 65%-96%)。
  • 中位PFS为11.0个月(95%CI 6.7-13.0个月),6个月PFS率为77%。
  • 中位OS为15.7个月(95%CI 12.3-23.8个月)。
  • Olvi-Vec剂量为经临时腹腔透析导管连续2天每日3×10^9 pfu/d。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些为假设生成性结果,值得在确证性3期试验中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with platinum-resistant or platinum-refractory ovarian cancer (PRROC) have limited therapeutic options, representing a considerable unmet medical need. OBJECTIVE: To assess antitumor activity and safety of intraperitoneal (IP) olvimulogene nanivacirepvec (Olvi-Vec) virotherapy and platinum-based chemotherapy with or without bevacizumab in patients with PRROC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, nonrandomized multisite phase 2 VIRO-15 clinical trial enrolled patients with PRROC with disease progression following their last prior line of therapy from September 2016 to September 2019. Data cutoff was on March 31, 2022, and data were analyzed between April 2022 and September 2022. INTERVENTIONS: Olvi-Vec was administered via a temporary IP dialysis catheter as 2 consecutive daily doses (3 × 109 pfu/d) followed by platinum-doublet chemotherapy with or without bevacizumab. MAIN OUTCOMES AND MEASURES: Primary outcomes were objective response rate (ORR) via Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) and cancer antigen 125 (CA-125) assay, and progression-free survival (PFS). Secondary outcomes included duration of response (DOR), disease control rate (DCR), safety, and overall survival (OS). RESULTS: Twenty-seven heavily pretreated patients with platinum-resistant (n = 14) or platinum-refractory (n = 13) ovarian cancer were enrolled. The median (range) age was 62 (35-78) years. The median (range) prior lines of therapy were 4 (2-9). All patients completed both Olvi-Vec infusions and chemotherapy. Median follow-up duration was 47.0 months (95% CI, 35.9 months to NA). Overall, ORR by RECIST 1.1 was 54% (95% CI, 33%-74%), with a DOR of 7.6 months (95% CI, 3.7-9.6 months). The DCR was 88% (21/24). The ORR by CA-125 was 85% (95% CI, 65%-96%). Median PFS by RECIST 1.1 was 11.0 months (95% CI, 6.7-13.0 months), and the PFS 6-month rate was 77%. Median PFS was 10.0 months (95% CI, 6.4-NA months) in the platinum-resistant group and 11.4 months (95% CI, 4.3-13.2 months) in the platinum-refractory group. The median OS was 15.7 months (95% CI, 12.3-23.8 months) in all patients, with a median OS of 18.5 months (95% CI, 11.3-23.8 months) in the platinum-resistant group and 14.7 months (95% CI, 10.8-33.6 months) in the platinum-refractory group. Most frequent treatment-related adverse events (TRAEs) (any grade, grade 3) were pyrexia (63.0%, 3.7%, respectively) and abdominal pain (51.9%, 7.4%, respectively). There were no grade 4 TRAEs, and no treatment-related discontinuations or deaths. CONCLUSIONS AND RELEVANCE: In this phase 2 nonrandomized clinical trial, Olvi-Vec followed by platinum-based chemotherapy with or without bevacizumab as immunochemotherapy demonstrated promising ORR and PFS with a manageable safety profile in patients with PRROC. These hypothesis-generating results warrant further evaluation in a confirmatory phase 3 trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02759588.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Holloway RW, Mendivil AA, Kendrick JE, et al. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023. PMID: 37227734. doi:10.1001/jamaoncol.2023.1007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。